|
Covered Companies
Cel-Sci Corporation - CVMThe WHO (I'm not kidding- World Health Organization) has officially declared the Swine Flu as a world wide pandemic. This past week, the WHO raised the Swine Flu to "Phase 6", it's highest level for global risk. The Phase 6 alert does not mean the severity is increasing- it means the spread is more global. The Phase 6 ranking opens the door to accelerated production and research on a number of possible therapies and vaccines. One company getting major recognition for a possible therapy is AMEX listed Cel-Sci (AMEX: CVM), a stock I have been following on and off for many years. Last week, CVM announced its L.E.A.P.S (Ligand Epitope Antigen Presentation System) technology, could represent an immune based therapy for swine flu, and had shown promise. At the Naval Medical Research Center in Silver Spring, MD, L.E.A.P.S has demonstrated an ability to enhance the body's natural protection against many different kinds of diseases. The Navy is focused on using the therapy to treat Malaria. This past week, Cel-Sci announced it was developing an immune based treatment for the Swine Flu, and the stock went absolutely ballistic. Cel-Sci traded 32 million shares in one day last week, the highest volume in its more than 20 years of being a publicly traded company under the ticker CVM. CVM also surged from about $.25 to $.80 in one day. Pretty crazy.
Quote Data
Business SummaryCEL-SCI Corporation, a biotechnology company, engages in research and development of drugs and vaccines for the treatment of cancer and infectious diseases. The company’s primary product Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines under phase II clinical trail for the treatment of cancer. It also develops CEL-1000 peptide product with its Ligand Epitope Antigen Presentation System technology which is under preclinical stage for the protection/treatment of animals against herpes, malaria, viral encephalitis, and cancer. The company markets its products to cancer centers, physicians, and clinics involved in immunotherapy. CEL-SCI was founded in 1983 and is based in Vienna, Virginia.
Disclosure
TGR Group LLC, an affiliate of MarketByte LLC, has been paid a fee of 100,000 newly issued restricted shares by Cel-Sci Corporation, for coverage of the Company.
Recent News HeadlinesThu, 02 Sep 2010 20:44:00 GMT Mon, 23 Aug 2010 17:46:00 GMT [Wall Street Transcript] - 67 WALL STREET, New York - August 23, 2010 - The Wall Street Transcript has just published its Semiconductors Report offering a timely review of the sector to serious investors and industry executives. This feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. <b>The full issue is available by calling (212) 952-7433 or via <a href="http://www.twst.com/tt/info/yhoo/info1969.htm">The Wall Street Transcript Online</a></b>. Fri, 20 Aug 2010 17:04:38 GMT Mon, 16 Aug 2010 22:05:06 GMT Mon, 16 Aug 2010 20:11:00 GMT [Business Wire] - VIENNA, Va.----CEL-SCI Corporation reported today financial results for its third fiscal quarter for the period ended June 30, 2010. Mon, 16 Aug 2010 20:05:40 GMT Fri, 13 Aug 2010 15:34:34 GMT Mon, 09 Aug 2010 20:42:33 GMT Fri, 06 Aug 2010 11:00:00 GMT Thu, 05 Aug 2010 13:15:00 GMT [GlobeNewswire] - CALGARY, Alberta -- Emerging Stock Report, a leading provider of sector specific independent investment research, today initiated coverage on CEL-SCI Corp. . Emerging Stock Report is currently offering a complimentary trial subscription to the investment community. Wed, 04 Aug 2010 15:00:00 GMT [Indie Research] - After soaring higher on the FDA approval of its Provenge prostate cancer vaccine in April, volatile Dendreon quickly retreated to well below its pre-approval pricing, but sales figures perked up the bulls on Wednesday. Wed, 04 Aug 2010 13:45:00 GMT [Business Wire] - VIENNA, Va.----CEL-SCI Corporation announced today that it has successfully produced and filled its first lot of Multikine® in preparation for the upcoming pivotal Phase III trial targeting advanced primary head and neck cancer. Mon, 28 Jun 2010 13:00:00 GMT [Business Wire] - VIENNA, Va.----CEL-SCI Corporation and researchers at the Northeastern Ohio Universities Colleges of Medicine and Pharmacy jointly announced today that a LEAPSTM–based vaccine study has demonstrated the technology’s potential using dendritic cells to stimulate the immune system to fight viral illnesses and other diseases. Mon, 17 May 2010 20:08:40 GMT Mon, 03 May 2010 17:03:34 GMT Mon, 03 May 2010 17:03:34 GMT Tue, 13 Apr 2010 12:47:00 GMT Fri, 12 Mar 2010 21:46:27 GMT Fri, 12 Mar 2010 12:00:00 GMT Thu, 18 Feb 2010 14:00:00 GMT |
Daily Blog
 
Newsletter
Editions To subscribe to our newsletter, please enter your email address below. 
Market Summary
|
